Last updated June 19, 2026
Key finding
Combination therapy achieved superior TIR (94.86 ± 3.65% vs. ~80% in monotherapies and 81.44% in control; P<0.001)
This study evaluated the combination therapy of Dapagliflozin and Linagliptin in managing Type 2 Diabetes and hypertension, showing significant improvements in various health metrics.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the combination therapy of Dapagliflozin and Linagliptin in managing Type 2 Diabetes and hypertension, showing significant improvements in various health metrics.
These findings are clinically significant as they suggest that combining these two medications can lead to better management of Type 2 Diabetes and hypertension, potentially reducing the risk of complications associated with these conditions. Improved metrics like HbA1c and blood pressure can enhance patient outcomes and quality of life.
Non-randomized design may introduce bias. Results may not be generalizable to all populations. Limited long-term follow-up data.
Published in
Publication details and source links for this paper.
WenXia L, RuRan L, ShanShan L, et al. Combination Therapy with Dapagliflozin and Linagliptin for Type 2 Diabetes and Hypertension. Frontiers in Endocrinology. 2026;17. doi:10.3389/fendo.2026.1802641
Combination therapy achieved a time in range of 94.86%, significantly higher than ~80% in monotherapies (P<0.001).
HbA1c levels decreased to 5.52%, indicating improved glycemic control.
Systolic blood pressure reduced to 124 mmHg, demonstrating effective hypertension management.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Dapagliflozin and Alanine Aminotransferase (ALT), Estimated glomerular filtration rate, Fasting Plasma Glucose (FPG), and 5 more.
This study contributes evidence to
Primary intervention
Dapagliflozin
Primary outcomes
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
4
Related topics
8
Evidence pairs
664
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
Related evidence
Evidence relationship
Save evidence
Evidence relationship
Save evidence
Core evidence
The primary outcomes reported in this study.
Dapagliflozin → Alanine Aminotransferase (ALT)
Dapagliflozin → Alanine Aminotransferase (ALT)
Dapagliflozin → Estimated glomerular filtration rate
Dapagliflozin → Estimated glomerular filtration rate
Dapagliflozin → Fasting Plasma Glucose (FPG)
Dapagliflozin → Fasting Plasma Glucose (FPG)
Dapagliflozin → Systolic blood pressure
Dapagliflozin → Systolic blood pressure
Dapagliflozin → Urinary albumin-to-creatinine ratio
Dapagliflozin → Urinary albumin-to-creatinine ratio
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on SGLT2 Inhibitors and HbA1c, SGLT2 Inhibitors and Fasting Glucose.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Medications
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring HbA1c
Measures HbA1c as a key outcome.
All studies on SGLT2 Inhibitors
Contributes to SGLT2 Inhibitors evidence base.
All studies measuring Blood Pressure
Measures Blood Pressure as a key outcome.
All studies measuring Fasting Glucose
Measures Fasting Glucose as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
6 results
3 results
6 results
6 results
3 results
Generated from the study's connected evidence using Evidence Intelligence™.
SGLT2 Inhibitors may improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 78.9 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 15 supporting studies with consistent results and a positive effect signal.
Limitations
SGLT2 Inhibitors may improve Kidney Function.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Urinary albumin-to-creatinine ratio
EvidenceScore™ Moderate | EvidenceScore™ 73.1 | strong positive | ConsistencyScore™ Consistent | 1 study
Estimated glomerular filtration rate
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is based on 8 supporting studies with consistent results and a positive effect signal.
Limitations
SGLT2 Inhibitors may improve Fasting Glucose.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Fasting Plasma Glucose (FPG)
EvidenceScore™ Strong | EvidenceScore™ 77.9 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 11 supporting studies with consistent results and a positive effect signal.
Limitations
SGLT2 Inhibitors may improve Adipokine and Angiogenic Markers.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Alanine Aminotransferase (ALT)
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 1 study
Triglycerides
EvidenceScore™ Moderate | EvidenceScore™ 63.1 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 7 supporting studies with consistent results and a positive effect signal.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
